Literature DB >> 2403813

Expression of human plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli as a soluble protein comprised of active and latent forms. Isolation and crystallization of latent PAI-1.

A E Franke1, D E Danley, F S Kaczmarek, S J Hawrylik, R D Gerard, S E Lee, K F Geoghegan.   

Abstract

Expression of human recombinant plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli has led to crystallization of 'latent' PAI-1. Cleavage with restriction endonucleases of a cDNA clone encoding PAI-1 yielded an 1127 base pair fragment encoding residues 2-376 of the 379 amino acid serpin. Synthetic DNA linkers were ligated to the 5' and 3' ends of the subclone to add an initiation codon and restore the full coding sequence, and the resulting semisynthetic gene was incorporated into an expression plasmid, pPAIST-7, under the control of the E. coli trp promoter. Transformation of E. coli GE81 with pPAIST-7 led to expression of unglycosylated PAI-1. Lysates of expression cultures contained PAI-1 activity and PAI-1 protein with the predicted Mr. Unglycosylated PAI-1 from E. coli exhibited characteristic properties of authentic PAI-1: (1) it was recovered in both active and inactive (latent) forms; (2) its activity declined during incubation at 37 degrees C; (3) latent PAI-1 was activated by treatment with 4 M guanidine hydrochloride; (4) reactivated PAI-1 formed a detergent-stable complex with tissue plasminogen activator. Latent PAI-1 accounted for more than 85% of PAI-1 in cell lysates and was purified by ammonium sulfate fractionation, anion-exchange chromatography and hydrophobic interaction chromatography. The purified latent PAI-1 was crystallized.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403813     DOI: 10.1016/0167-4838(90)90096-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Distinguishing between sequential and nonsequentially folded proteins: implications for folding and misfolding.

Authors:  C J Tsai; J V Maizel; R Nussinov
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

Review 2.  Insights from bacterial subtilases into the mechanisms of intramolecular chaperone-mediated activation of furin.

Authors:  Ujwal Shinde; Gary Thomas
Journal:  Methods Mol Biol       Date:  2011

3.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.

Authors:  E L Madison; E J Goldsmith; R D Gerard; M J Gething; J F Sambrook; R S Bassel-Duby
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima.

Authors:  Chung-Jung Tsai; Zuben E Sauna; Chava Kimchi-Sarfaty; Suresh V Ambudkar; Michael M Gottesman; Ruth Nussinov
Journal:  J Mol Biol       Date:  2008-08-12       Impact factor: 5.469

6.  Modeling protein folding in vivo.

Authors:  Irina Sorokina; Arcady Mushegian
Journal:  Biol Direct       Date:  2018-07-06       Impact factor: 4.540

Review 7.  Development and Testing of Thrombolytics in Stroke.

Authors:  Dmitri Nikitin; Seungbum Choi; Jan Mican; Martin Toul; Wi-Sun Ryu; Jiri Damborsky; Robert Mikulik; Dong-Eog Kim
Journal:  J Stroke       Date:  2021-01-31       Impact factor: 6.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.